CellFE and Made Scientific Join Forces to Revolutionize Non-viral Gene Editing in T Cell Therapies

Strategic Partnership in Cell Therapy



In a significant development for the field of cell therapy, CellFE and Made Scientific have announced a strategic collaboration focused on pioneering non-viral gene editing techniques, specifically for T cell therapies. CellFE, renowned for its advanced microfluidics technology, and Made Scientific, an industry leader in cell therapy contract development and manufacturing, are setting the stage for innovation that promises to enhance the efficacy and accessibility of cellular therapies.

Objectives of the Collaboration



The primary goal of this partnership is to generate pilot data utilizing the CellFE High Volume Cyva™ System. This system is expected to validate and enhance clinical-scale performance for therapies involving both activated and resting T cells. Two distinct workflows will be assessed during the pilot program.

The first workflow will employ activated T cells, leveraging both non-viral and viral gene editing methods to rapidly produce personalized autologous T cell products. This approach is crucial, especially with the ever-growing demand for individualized immunotherapies.

The second workflow examines quiescent or resting T cells, aiming for the first proof of concept in developing an allogeneic resting T cell therapeutic approach. This innovative strategy holds promise for creating off-the-shelf cell therapy solutions, which could significantly decrease treatment timelines and broaden patient access to these potentially life-saving therapies.

Leveraging Expertise



Under this strategic agreement, CellFE has chosen Made Scientific to conduct the pilot-scale studies, capitalizing on its state-of-the-art manufacturing capabilities and in-depth expertise in cell therapy process development. This collaboration is poised to highlight the scalability of CellFE's microfluidics platform, which is engineered to maintain cell health, maximize yields, and facilitate intricate genome editing without relying on viral vectors. These advancements aim to tackle challenges such as high manufacturing costs and extended production timelines that currently hinder the delivery of advanced cell therapies to those who need them most.

Dr. Alla Zamarayeva, CEO and Co-founder of CellFE, expressed her enthusiasm about the partnership, stating, "By combining our groundbreaking microfluidic gene editing with Made Scientific's premier CDMO services, we are set to establish a new standard in engineered T cell therapy production. The data we generate together will be pivotal for supporting the clinical scaling of our technology."

Syed T. Husain, Chairman and CEO of Made Scientific, echoed these sentiments, commenting on the partnership’s unique potential. "This collaboration with CellFE offers an exceptional opportunity to push forward innovative non-viral gene editing solutions. By merging our specialized T cell manufacturing capabilities with CellFE's cutting-edge microfluidics technology, we aim to enhance quality and speed up production timelines while addressing the specific needs of groundbreaking therapies."

Future Directions and White Paper



The outcomes from the pilot program are anticipated to be significant and will be documented in a forthcoming white paper set to be shared with the cell and gene therapy community by October 2025. This publication promises to shed light on the advancements made through this collaboration and pave the way for future research and applications in the cell therapy domain.

About the Companies



CellFE



As a trailblazer in microfluidics technology, CellFE is committed to revolutionizing the development and manufacturing processes of life-saving cell therapies. The company seeks to dismantle key market barriers such as high production costs and lengthy timelines from vein to treatment. By focusing on T-cell, HSC, and iPSC-based therapies, CellFE's innovative gene-delivery technology addresses critical issues within cell therapy manufacturing.

Made Scientific



Made Scientific specializes in advancing the realm of cell therapy as a leading contract development and manufacturing organization (CDMO). Established in 2019, the organization has evolved into a full-service provider from clinical to commercial needs. Operating two manufacturing facilities in the United States, Made Scientific combines the agility of a specialist CDMO with the vast expertise and resources of GC Corporation, a prominent player in the global pharmaceutical and biotechnology industry.

For further inquiries and additional information, both companies encourage reaching out via their respective contact emails, ensuring open channels for discussions on this groundbreaking initiative.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.